Most Awaited Q3 Sale is back. Upto 30% discount on every report.

Pseudomonas Aeruginosa Infection Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 March 23
SKU : HOS2668
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Pseudomonas Aeruginosa Infection Treatment Market is segmented By Treatment (Monotherapy, Combination Therapy), By Drug Class (Aminoglycoside, Monobactam, Carbapenem, Cephalosporin, Others), By Route of Administration (Nasal, Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030


Pseudomonas Aeruginosa Infection Treatment Market Overview

Report on Global Pseudomonas Aeruginosa Infection Treatment Market size was valued at US$ 1331.51 million in 2022 and is estimated to reach US$ 2019.81 million by 2030, growing at a CAGR of 5.4% during the forecast period 2023-2030. Demand from healthcare in North America is booming. Competitive rivalry intensifies with AbbVie Inc, Gilead Sciences Inc, Pfizer Inc and others operating in the market.

Pseudomonas Aeruginosa (also known as P. aeruginosa) is an important cause of gram-negative infection, especially in patients with compromised host defense mechanisms. Pseudomonas aeruginosa is a multidrug-resistant pathogen known for its intrinsically advanced antibiotic resistance mechanisms, its antibiotic resistance mechanisms, and its association with serious illnesses including hospital-acquired infections (HAIs) such as ventilator-associated pneumonia and various sepsis syndromes. These bacteria frequently cause urinary tract infections (UTIs), lung infections, pneumonia, and chronic pain. People with a low immune system are highly prone to affect by this infection. The incidence of Hospital Acquired Infections (HAIs) has increased in recent years. As P. aeruginosa infection is one of the common infections in a hospital facility, the chances of being diagnosed with P. aeruginosa infection are high. This has led to an increase in research and development to find the treatment for P. aeruginosa. Several drugs are in the pipeline phases for the treatment of this infection.

  • As Pseudomonas Aeruginosa infection is one of the most common infections in hospitals, the chances of being diagnosed with it are high. As a result, the Global Pseudomonas Aeruginosa Infection Treatment Market is expected to grow significantly in the coming years, owing to the increasing incidence and prevalence of hospital-acquired infections such as gastrointestinal infections, urinary tract infections, and respiratory system infections around the world. These factors are projected to considerably boost worldwide market expansion.
  • Furthermore, one of the primary reasons driving market expansion is the high mortality rate owing to infection. Furthermore, as bacteria are the potential of acquiring resistance to frequently used antibiotics such as carbapenems and aminoglycosides, the increased usage of antibiotics for their treatment drives the market's rise throughout the projection period. Increasing R&D initiatives to enhance treatment alternatives, as well as increased investment in research programs by corporate and non-profit organizations, are fuelling market expansion.
  • The growing demand for pseudomonas aeruginosa therapy due to the severe symptoms it causes, as well as the fact that some persons are more susceptible to contracting the infection due to a compromised immune system, has an impact on worldwide market growth. In addition, an increase in the prevalence of co-morbidities such as cystic fibrosis, pneumonia, urinary tract infection, and bloodstream infection has a beneficial influence on the growth of the pseudomonas aeruginosa treatment market. Furthermore, the worldwide market will profit from rising demand for innovative medicines, technical progress, and regulatory approvals, all of which are likely to give lucrative prospects to market participants throughout the forecast period.

As per DataM Intelligence, Pseudomonas Aeruginosa Infection Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Pseudomonas Aeruginosa Infection Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, North America has the highest revenue share in the Global Pseudomonas Aeruginosa Infection Treatment Market and is likely to maintain its position during the forecast period, followed by the European region. The rising incidence of antibiotic-resistant diseases, as well as continuing projects, the development of novel treatments, and the launch of several pharmaceuticals into the North American market are primarily responsible for revenue growth in the industry.

Recent Developments in the Industry:

  1. In April 2021, CARB-X funded up to 5.3 million USD to Phico therapeutics to develop an engineered bacteriophage drug to treat ventilator-associated pneumonia caused by drug-resistant pseudomonas aeruginosa.
  2. In May 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., launched generic erythromycin tablets in the USA. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin. The tables are available in sizes of 250 mg and 500 mg.
  3. In September 2019, Armata Pharmaceuticals, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa to treat serious respiratory infections, with an emphasis on cystic fibrosis patients.
  4. In March 2019, Allergan received the U.S. FDA approval for the AVYCAZ treatment of complicated intra-abdominal infections (cIAI) and urinary tract infections (cUTI) in pediatric patients.


Pseudomonas Aeruginosa Infection Treatment Market Scope and Summary



Market CAGR


Segments Covered

 By Treatment, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

Report Insights Covered

 Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

 Asia Pacific

Largest Market Share 

 North America


To Get a Free Sample  Click here


Pseudomonas Aeruginosa Infection Treatment Market Trends and Dynamics

rising incidences of nosocomial infections associated with P. aeruginosa

The pseudomonas aeruginosa infection treatment market growth is majorly driven by the rising incidences of nosocomial infections associated with P. aeruginosa, rapidly growing antibacterial resistance, and increasing research & development of pseudomonas aeruginosa infection treatments.

  • The rise in the prevalence of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others, are expected to drive the growth of the global pseudomonas aeruginosa infection treatment market over the forecast period. There is a rise in the incidence of pseudomonas aeruginosa infections in intensive care which is projected to boost the demand for newer pseudomonas aeruginosa infection treatment drugs.
  • As per the Centers for Disease Control and Prevention (CDC), about 51,000 healthcare-associated pseudomonas aeruginosa infections occur in the United States annually. Over 6,000 (13%) of these are multidrug-resistant, with around 400 deaths per year attributed to these infections. The growing mortality rate owing to hospital-acquired infection(HAIs) is caused due to P. aeruginosa bacteria, especially in immunocompromised hosts. About 35 % of healthcare-acquired infections cause respiratory system infections, urinary infections, gastrointestinal infections, and other disorders, which leads to a rise in the demand for pseudomonas aeruginosa treatment.
  • In addition, increasing the usage of antibiotics for the treatment of pseudomonas aeruginosa infection is also driving market growth. Owing to the increasing use of antibiotics for the treatment of P. aeruginosa infection, the emergence of antibiotic-resistant bacterial strains has this line of treatment almost ineffective. In this scenario, pharma companies are focused on developing a treatment approach for the same. This provides ample white space for players in the pseudomonas aeruginosa infection treatment market to capitalize on.
  • The rising investments and extensive research & development are boosting the development of novel therapies. The major players are investing heavily in R&D for non-antibiotic treatment options. Several pharma companies are testing novel compounds that bear chemical similarities with antibiotics. Increasing funding for research and development is expected to boost market growth. For instance, in November 2021, PlateletBio, a preclinical stage company that invested in developing a new approach to allogeneic cell therapies, raised $75.5 million in a Series B financing round to advance its pioneering approach to the field.
  • The company is developing new allogeneic cell therapies based on platelet biology. Its lead candidate is in preclinical development for immune thrombocytopenia (ITP), an autoimmune disease. Also, in July 2022, Carmot Therapeutics, Inc., a clinical-stage biotechnology company announced to invest 160 million USD financing for drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer.

However, extended use of antibiotics leads to harmful effects on the patient, which is likely to hamper the market growth. However, as P. aeruginosa shows the ability of drug resistance, several drug developers, who have limited funds are dissuaded from the market.

Pseudomonas Aeruginosa Infection Treatment Market Segmentation Analysis

Therapy segment for the highest share in the global market for pseudomonas aeruginosa infection treatment;

By Treatment:

  • Monotherapy
  • Combination Therapy

By Drug Class:

  • Aminoglycoside
  • Monobactam
  • Carbapenem
  • Cephalosporin
  • Others

By Route of Administration:

  • Nasal
  • Oral
  • Intravenous

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

The pseudomonas aeruginosa infection treatment market is classified by medication into monotherapy and combination therapy. Among these, the combination therapy segment accounted for the largest market share in the global market for pseudomonas aeruginosa infection treatment in 2021. Combination therapy is used for patient who has developed resistance property against monotherapy. During this therapy, a combination of different drugs is used to treat bacterial infections. The rise in drug resistance in monotherapy has increased the demand for combination therapy for the treatment of pseudomonas aeruginosa infection.

As per the research, combination therapy showed promising results and the mortality was lower in patients receiving combination therapy, compared to monotherapy.  Also, the growth of combination therapy for the treatment of P. aeruginosa infection is due to its rapid onset of action, high bioavailability rate, cost-saving, and high efficiency. Hence, these factors are expected to boost the growth of the combination therapy segment.

Based on drug class,the cephalosporin segment held the largest market share in 2019, owing to the increasing development of a new class of cephalosporin for the treatment of various P. aeruginosa infections by significant companies. A new cephalosporin (fifth-generation) was developed for the treatment of gram-negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. The launch of a new cephalosporin class of drugs is likely to boost the growth of the segment.

The intravenous segment is expected to dominate the global market during the forecast period because most of the drugs available for the intravenous route as it gives rapid onset of action and high accuracy in dosing compared with other routes. Most physicians prefer the intravenous route for the administration of drugs, as in the intravenous route, the entire dose reaches the systemic circulation immediately with rapid onset of action against bacteria.

Global Pseudomonas Aeruginosa Infection Treatment Market Geographical Share

North America is the dominating region during the forecast period.

  • North America region is dominating the global market for pseudomonas aeruginosa infection treatment and accounted for the largest market share in 2021, owing to rising incidences of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others. The Centers for Disease Control (CDC) estimates that HAIs account for an estimated 1.7 million infections and 99,000 associated deaths each year. In addition, 32 percent of all healthcare-acquired infections are urinary tract infections and 22 percent are surgical site infections.
  • According to the Provincial Infection Control Network of British Columbia, HAIs are a major patient safety issue and economic burden for the healthcare system.  In Canada, one in every nine hospital patients contracts a healthcare-associated infection. It is estimated that each year in Canada, there are more than 220,000 cases of HAI in Canadian hospitals, resulting in at least 8,000 deaths. As Pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries.
  • The U.S. and Canada have well-developed healthcare system that encourages research and development for the treatment of these infections. These countries have a major presence of diverse global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.
  • Europe is the second-largest market for pseudomonas aeruginosa infection treatment in terms of market value, due to rising incidences of pseudomonas aeruginosa infection, the presence of major players, and the early adoption of new products. For instance, in Germany, about 22,000 to 33,000 people are suffering from pseudomonas aeruginosa infection.
  • The Asia-Pacific market for pseudomonas aeruginosa infection treatment is expected to grow at the fastest growth rate over the forecast period. Developing countries such as China, India, and South Korea are expected to be lucrative markets over the forecast period, owing to growing awareness, increasing incidences of healthcare-associated pseudomonas aeruginosa infection, rapidly developing healthcare infrastructure and high demand for advanced therapeutics. About 165,000 to 180,000 people in Australia suffer from hospital-acquired infections, as per a study, and of these, about 9,000 have pseudomonas aeruginosa infection.

Pseudomonas Aeruginosa Infection Treatment​​​​​​​ Companies and Competitive Landscape

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance. The global players are manufacturing the majority of the pseudomonas aeruginosa infection treatment drugs and therapies. Some of the key players which are contributing to the growth of the market include; AbbVie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd, Pfizer, Inc, Merck & Co., Inc, AstraZeneca, Bristol-Myers Squibb Co, Lupin Pharmaceuticals, Inc, Janssen Pharmaceuticals, Inc, Gilead Sciences Inc, and Novartis AG.


Trending Topics

Infection Control Market

UV Infection Control Devices Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
Request new version